Labelling, Artwork & Promotional Compliance
Labelling is the one regulated output that reaches the patient directly, and the boundary around what a company may say about its product is drawn by the authorisation rather than by the marketing plan. A claim beyond the authorisation is an enforcement matter, not a positioning dispute. Artwork error, meanwhile, is a recurring cause of recall — which makes labelling a place where the regulatory question and the quality question are the same question.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 24 LINKSArtwork is a regulated document that behaves like a design file: it is versioned, approved and reproduced at scale, and an error in it reaches every unit made before anyone notices.
06 · QUALITY MATURITY — LABELLING, ARTWORK & PROMOTIONAL COMPLIANCE, REACTIVE TO ADAPTIVE
Artwork is managed by whoever is producing the pack. Approved text lives in several places and they have drifted.
A controlled artwork process exists with defined approvals, but the source text is transcribed into it rather than drawn from the approved label.
One controlled source of approved text feeds every artwork, changes are traced from the regulatory decision through to the printed component, and reconciliation is verified rather than assumed.
Implementation timing is managed against approval dates and stock, so a required change reaches the market when it must and old stock is dispositioned deliberately.
Artwork, label and promotional claims share one governed source, so a change made once is correct everywhere and cannot diverge between markets.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 5
Derived from the 5 standards SPEQ maps to this subject, across 2 regulatory bodies: FDA, EC.
RECORDS & OBJECTIVE EVIDENCE
- The approved label text and its controlled source of truth
- Artwork version history with approvals, including regulatory sign-off
- Proofing and reconciliation records against approved text
- Change implementation records showing effective dates and stock disposition
- Promotional material review and approval records, with the claims substantiated
COMMON INSPECTION FINDINGS
- Artwork text transcribed rather than drawn from the approved source, with drift between them
- A label change approved by the authority and not implemented by the required date
- Old artwork still in use after a change, with no stock disposition decision
- Promotional claims exceeding the approved indication or unsupported by the dossier
- Market-specific artwork diverging with no controlled reason
What the label must say, and the misbranding trap
21 CFR Part 201 governs the labelling of human drugs: what must appear on the label, and the content and format of prescription-drug labelling under §201.56 and §201.57 — the Highlights, Contents and Full Prescribing Information structure. In the EU, Title V of Directive 2001/83/EC sets the corresponding requirements for labelling and the package leaflet, including readability and language obligations that vary by Member State.
The provision worth reading closely is §201.10: a drug is misbranded if its labelling is false or misleading in any particular — including by omission. A label can be technically accurate in every statement it makes and still misbrand because of what it leaves out. This is why labelling review cannot be a proofreading exercise against a checklist; it has to ask what impression the labelling as a whole creates.
Artwork is where compliance actually fails
The regulation is rarely misread. What goes wrong is version control. Artwork changes follow a launch date or a marketing timeline rather than change control, and an unapproved version reaches print. The result is a labelling non-conformance discovered in the market, which is one of the most common recall causes and one of the least defensible, because the failure is administrative rather than technical.
The controls are straightforward and often absent: artwork and labelling under formal change control, with proofing against the approved text as the release step — not as a review someone performs earlier in the cycle. And translations treated as a regulated activity verified back to the approved source by someone qualified to judge meaning, rather than as a linguistic task where drift from the approved text is invisible to the reviewer.
Promotion is bounded by the authorisation
In the US, 21 CFR Part 202 governs prescription-drug advertising: the true-statement requirement in §202.1(e), a brief summary of side effects, contraindications and effectiveness, fair balance between benefit and risk information, and the categories of presentation FDA treats as false or misleading in §202.1(e)(6). Broadcast advertisements may use the adequate-provision alternative instead of a full brief summary. In the EU, Title VIIIa of Directive 2001/83/EC restricts advertising to the terms of the summary of product characteristics.
Fair balance is judged on the presentation as a whole, including relative prominence — not on whether risk information appears somewhere. And the boundary between advertising and promotional labelling matters: material that is not an advertisement is reached through the labelling provisions instead, which is why promotional review has to consider both regimes rather than picking one.
Review against the authorisation, not the brand
The failure pattern is a promotional review that checks brand consistency, legal risk and tone, but never checks the claim against the authorised indication and the approved safety information. It appears in FDA untitled and warning letters year after year, and it is a process gap rather than an intent problem: nobody in the review chain was accountable for holding the material against the authorisation.
The control is regulatory and medical sign-off against the authorisation as a required step, and a record of which approved labelling version the reviewer checked against. That last part matters more than it sounds — the approved labelling moves, and a promotional claim that was accurate against last year’s version is not thereby accurate now.
SPEQ interpretation — labelling belongs to both functions and is owned by neither
Labelling sits on a seam. Regulatory affairs owns the approved text, supply chain owns the artwork and print, marketing owns the promotional material, and quality owns the change control that should govern all three. The predictable consequence is that each function assumes another is holding the control, and the version that reaches print is the one whose route through the organisation nobody was watching.
SPEQ’s view is that the useful test is a single question asked of any labelling or promotional output: which approved version was this checked against, and who recorded that check? An organisation that cannot answer it for a given artwork or a given piece of promotional material does not have a labelling control system — it has several partial ones.
FREQUENTLY ASKED
What makes a drug misbranded under 21 CFR Part 201?
Labelling that is false or misleading in any particular, which §201.10 makes explicit includes misleading by omission. A label whose individual statements are each accurate can still misbrand if the overall impression it creates is not — which is why labelling review has to assess the whole, not tick off required elements.
What is fair balance in prescription-drug advertising?
A presentation of risk information comparable in prominence and readability to the benefit claims, judged on the advertisement as a whole under 21 CFR §202.1. Including required risk text somewhere does not satisfy it — relative prominence, placement and readability are part of the assessment.
Are translations of approved labelling a regulatory activity?
Yes. A translation is labelling in that market, and meaning can drift from the approved source in ways a linguistic review will not catch. Verify translations back to the approved text, by someone qualified to judge whether the regulated meaning survived — not only whether the language reads well.
Why is artwork such a common recall cause?
Because the failure is administrative rather than technical. Artwork changes that follow a launch timeline instead of change control let an unapproved version reach print, and the error is discovered in the market. Proofing against the approved text as the release step — not as an earlier review — is what catches it.